000			01945 a2200517 4500
005			20250516144159.0
264		0	_c20150707
008			201507s 0 0 eng d
022			_a1873-7560
024	7		_a10.1016/j.eururo.2013.03.055 _2doi
040			_aNLM _beng _cNLM
100	1		_aCalais da Silva, Fernando
245	0	0	_aLocally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. _h[electronic resource]
260			_bEuropean urology _cAug 2014
300			_a232-9 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xblood
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aCyproterone Acetate _xadministration & dosage
650	0	4	_aDisease Progression
650	0	4	_aEurope
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProstate-Specific Antigen _xblood
650	0	4	_aProstatic Neoplasms _xblood
650	0	4	_aQuality of Life
650	0	4	_aSexuality
650	0	4	_aSurvival Rate
650	0	4	_aTime Factors
650	0	4	_aTriptorelin Pamoate _xadministration & dosage
700	1		_aCalais da Silva, Fernando Manuel
700	1		_aGonçalves, Frederico
700	1		_aSantos, Américo
700	1		_aKliment, Jan
700	1		_aWhelan, Peter
700	1		_aOliver, Tim
700	1		_aAntoniou, Nicos
700	1		_aPastidis, Spiro
700	1		_aMarques Queimadelos, Anton
700	1		_aRobertson, Chris
773	0		_tEuropean urology _gvol. 66 _gno. 2 _gp. 232-9
856	4	0	_uhttps://doi.org/10.1016/j.eururo.2013.03.055 _zAvailable from publisher's website
999			_c22666378 _d22666378